These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 24287186)

  • 1. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial.
    Palmu AA; Jokinen J; Nieminen H; Rinta-Kokko H; Ruokokoski E; Puumalainen T; Borys D; Lommel P; Traskine M; Moreira M; Schuerman L; Kilpi TM
    Lancet Infect Dis; 2014 Mar; 14(3):205-12. PubMed ID: 24287186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial.
    Palmu AA; Jokinen J; Nieminen H; Syrjänen R; Ruokokoski E; Puumalainen T; Moreira M; Schuerman L; Borys D; Kilpi TM
    Lancet Respir Med; 2014 Sep; 2(9):717-27. PubMed ID: 25127244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
    Palmu AA; Jokinen J; Borys D; Nieminen H; Ruokokoski E; Siira L; Puumalainen T; Lommel P; Hezareh M; Moreira M; Schuerman L; Kilpi TM
    Lancet; 2013 Jan; 381(9862):214-22. PubMed ID: 23158882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial.
    Kilpi TM; Jokinen J; Puumalainen T; Nieminen H; Ruokokoski E; Rinta-Kokko H; Traskine M; Lommel P; Moreira M; Ruiz-Guinazu J; Borys D; Schuerman L; Palmu AA
    Vaccine; 2018 Sep; 36(39):5891-5901. PubMed ID: 30145098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine in a cluster-randomised trial.
    Rinta-Kokko H; Palmu AA; Ruokokoski E; Nieminen H; Moreira M; Schuerman L; Borys D; Jokinen J
    PLoS One; 2022; 17(1):e0261750. PubMed ID: 34986178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial.
    Palmu AA; Jokinen J; Nieminen H; Rinta-Kokko H; Ruokokoski E; Puumalainen T; Moreira M; Schuerman L; Borys D; Kilpi TM
    Vaccine; 2018 Mar; 36(14):1816-1822. PubMed ID: 29503110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the 10-valent pneumococcal conjugate vaccine among girls, boys, preterm and low-birth-weight infants - Results from a randomized, double-blind vaccine trial.
    Nieminen H; Rinta-Kokko H; Jokinen J; Puumalainen T; Moreira M; Borys D; Schuerman L; Palmu AA
    Vaccine; 2019 Jun; 37(28):3715-3721. PubMed ID: 31122856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of the Ten-valent Pneumococcal Conjugate Vaccine Against Tympanostomy Tube Placements in a Cluster-randomized Trial.
    Palmu AA; Jokinen J; Nieminen H; Rinta-Kokko H; Ruokokoski E; Puumalainen T; Traskine M; Moreira M; Borys D; Schuerman L; Kilpi TM
    Pediatr Infect Dis J; 2015 Nov; 34(11):1230-5. PubMed ID: 26284652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
    Tregnaghi MW; Sáez-Llorens X; López P; Abate H; Smith E; Pósleman A; Calvo A; Wong D; Cortes-Barbosa C; Ceballos A; Tregnaghi M; Sierra A; Rodriguez M; Troitiño M; Carabajal C; Falaschi A; Leandro A; Castrejón MM; Lepetic A; Lommel P; Hausdorff WP; Borys D; Ruiz Guiñazú J; Ortega-Barría E; Yarzábal JP; Schuerman L;
    PLoS Med; 2014 Jun; 11(6):e1001657. PubMed ID: 24892763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age.
    Karppinen S; Toivonen L; Schuez-Havupalo L; Teros-Jaakkola T; Waris M; Auranen K; Palmu AA; Peltola V
    Vaccine; 2019 May; 37(22):2935-2941. PubMed ID: 31027929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.
    Sáez-Llorens X; Rowley S; Wong D; Rodríguez M; Calvo A; Troitiño M; Salas A; Vega V; Castrejón MM; Lommel P; Pascal TG; Hausdorff WP; Borys D; Ruiz-Guiñazú J; Ortega-Barría E; Yarzabal JP; Schuerman L
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-16. PubMed ID: 28368738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
    Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
    Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland.
    Vesikari T; Forsten A; Seppä I; Kaijalainen T; Puumalainen T; Soininen A; Traskine M; Lommel P; Schoonbroodt S; Hezareh M; Moreira M; Borys D; Schuerman L
    J Pediatric Infect Dis Soc; 2016 Sep; 5(3):237-248. PubMed ID: 27125273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the 10-valent pneumococcal conjugate vaccine on antimicrobial prescriptions in young children: a whole population study.
    Eythorsson E; Sigurdsson S; Hrafnkelsson B; Erlendsdóttir H; Haraldsson Á; Kristinsson KG
    BMC Infect Dis; 2018 Oct; 18(1):505. PubMed ID: 30286726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct and Indirect Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine Against Carriage in a Cluster Randomized Trial.
    Palmu AA; Toropainen M; Kaijalainen T; Siira L; Lahdenkari M; Nieminen H; Syrjänen RK; Kilpi TM; Jokinen J
    Pediatr Infect Dis J; 2017 Dec; 36(12):1193-1200. PubMed ID: 28737627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.
    Prymula R; Peeters P; Chrobok V; Kriz P; Novakova E; Kaliskova E; Kohl I; Lommel P; Poolman J; Prieels JP; Schuerman L
    Lancet; 2006 Mar; 367(9512):740-8. PubMed ID: 16517274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 10-Valent pneumococcal non-typeable
    Oguoma VM; Wilson N; Mulholland K; Santosham M; Torzillo P; McIntyre P; Smith-Vaughan H; Balloch A; Chatfield M; Lehmann D; Binks MJ; Chang A; Carapetis J; Krause V; Andrews R; Snelling T; Licciardi P; Morris P; Leach AJ
    BMJ Open; 2020 May; 10(5):e033511. PubMed ID: 32448790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life.
    Silfverdal SA; Skerlikova H; Zanova M; Papúchová D; Traskine M; Borys D; Schuerman L
    Pediatr Infect Dis J; 2011 Sep; 30(9):e155-63. PubMed ID: 21572373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.